Colin Begg

Chairman, Attending Biostatistician

Office Phone


Office Fax



Current Research Interests

Explore career opportunities in the Department of Epidemiology and Biostatistics.
Learn more

Dr. Begg is interested in cancer epidemiology, health services research, clinical trials, and the statistical methods that support scientific studies in these disciplines.  In recent years he has been pursuing the idea that cancer risk can be uniquely informed by studying patients with multiple primary malignancies. Currently his work on this topic is focused on three areas. In the first, he is developing models for estimating the cancer risks of rare genetic variants. In the second area he has been developing statistical techniques for clonality assessment, used to distinguish independent second primary cancers from metastases on the basis of the somatic molecular profiles of the tumors. In the third area of investigation, he is developing methods for using somatic profiles of double primary malignancies to make inferences of about the etiologic heterogeneity of tumor sub-types. He collaborates closely with various other members of the department on these projects, notably Drs Bernstein, Capanu, Ostrovnaya and Seshan.

Mutations that cause cancer: A Q&A session with Drs. Marinela Capanu and Colin Begg


University of Glasgow, UK


Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL. Variation of breast cancer risk among BRCA1/2 carriers: An investigation by the WECARE Study Group. JAMA 2008; 299:194-201. [PubMed Abstract]

Capanu M, Begg CB. Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood method. Biometrics 2011;67:371-380. [PubMed Abstract]

Begg, CB. A strategy for distinguishing optimal cancer subtypes. International Journal of Cancer 2011;129:931-937. [PubMed Abstract]

Ostrovnaya I, Seshan VE, Olshen A, Begg CB. Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics 2011;27:1698-1699. [PubMed Abstract]

Begg CB, Zabor E. Detecting and exploiting etiologic heterogeneity in epidemiologic studies. American Journal of Epidemiology 2012 (in press).

Read more

  1. Gavras H, Oliver N, Aitchison J, Begg C, Briggs JD, Brown JJ, Horton PW, Lee F, Lever AF, Prentice C, Robertson JIS. Abnormalities of coagulation and the development of malignant-phase hypertension. Kidney Int 1975; 5:254-263.

  2. Aitchison J, Begg CB. Statistical diagnosis when basic cases are not classified with certainty. Biometrika 1976; 63:1-12.

  3. Howie PW, Purdie DW, Begg CB, Prentice CRM. Use of coagulation tests to predict the clinical progression of pre-eclampsia. Lancet 1976; 2:323-326. [PubMed Abstract]

  4. Horton J, Begg CB, Arsenault J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 1978; 62:159-161. [PubMed Abstract]

  5. Begg CB, Mehta CR. Sequential analysis of comparative clinical trials. Biometrika. 1979; 66:97-104.

  6. Chiuten DF, Creech RH, Glick J, Falkson G, Brodovsky H, Begg CB, Muggia FM, Carbone PP. VM-26: A new anticancer drug with effectiveness in malignant lymphoma. Cancer Treat Rep 1979; 63:7-11. [PubMed Abstract]

  7. DeWys WD, Begg CB, Slayton R, Hahn RG, Brodsky I. Preliminary Report of an Eastern Cooperative Group Study: EST 1877. Cancer Treat Rep 1979; 63:1675-1680. [PubMed Abstract]

  8. Begg CB, Iglewicz B. A treatment allocation procedure for sequential clinical trials. Biometrics 1980; 36:81-90. [PubMed Abstract]

  9. DeWys WD, Begg CB, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, and Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Amer J Med Treat Rep 1980; 69:491-497. [PubMed Abstract]

  10. Begg CB, Bennett JM, Cassileth PA. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: An alternative perspective. N Engl J Med 1980; 302:408-409. [PubMed Abstract]

  11. Begg CB, Cohen J, Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy: A study involving data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 1980; 3:369-374. [PubMed Abstract]

  12. O’Connell MJ, Begg CB, Silverstein MN, Glick JH, Oken MM. A randomized clinical trial comparing two dosage regimens of ICRF-159 in refractory malignant lymphomas. Cancer Treat Rep 1980; 64:1355-1358. [PubMed Abstract]

  13. DeWys WD, Begg CB, Band RR, Tormey DC. The impact of malnutrition on treatment results in breast cancer. Cancer Treat Rep 1981; 65:87-91.

  14. Bennett JM, Begg CB. The cytochemistry of adult acute myeloid leukemia: correlation of subtypes with response and survival. Cancer Res 1981; 41:4833-4837. [PubMed Abstract]

  15. Stolbach LL, Begg CB, Hall T, Horton J. Treatment of renal carcinoma. A phase III study of Oral Medroxyprogesterone (Provera), Hydroxyurea, and UII, 100A (Nafoxidine). Cancer Treat Rep 1981; 65:689-692. [PubMed Abstract]

  16. Rubin P, Bennett JM, Begg CB, Zagars G. The comparison of Total Body Irradiation vs. Chlorambucil and Prednisone for remission induction of active chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 1981; 7:1623-1632.

  17. Hahn RG, Begg CB, Davis TED. Phase II study of Vinblastine-CCNU, Triazinate and Actinomycin-D in advanced renal cell cancer. Cancer Treat Rep 1981; 65:711-714. [PubMed Abstract]

  18. Begg CB, Larson M. A study of the use of the probability of being in response function as a summary of tumor response data. Biometrics 1982; 38:59-66. [PubMed Abstract]

  19. Rudders RA, Ahl ET, DeLellis RA, Bernstein S, Begg CB. Surface marker identification of small cleaved follicular center cell (SCFCC) lymphomas with a highly favorable prognosis. Cancer Res 1982; 42:349-353. [PubMed Abstract]

  20. Stolbach L, Begg CB, Bennett JM, Silverstein M, Falkson G, Harris DT, and Glick J. Evaluation of bone marrow toxicity in patients treated with allopurinol. JAMA 1982; 247: 334-336.

  21. Begg CB, Elson PJ, McFadden E, Zelen M, Carbone PP. Quality of institutional participation of multicenter clinical trials: The ECOG experience. N Engl J Med 1982; 306(13):813.

  22. Begg CB, Carbone PP, Elson P, Zelen M. Participation of community hospitals in cancer clinical trials: Analysis of five years experience in the Eastern Cooperative Oncology Group (with editorial). N Engl J Med 1982; 306:1076-1080. [PubMed Abstract]

  23. Begg CB and Greenes R. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 1983; 39:207-216. [PubMed Abstract]

  24. Wijesinha A, Begg CB, Funkenstein HH, McNeil BJ. Methodology for differential diagnosis of a complex data-set: a case-study using data from routine CT-scan examinations. Med Decis Making 1983; 3:133-154. [PubMed Abstract]

  25. Begg CB, Zelen M, Carbone PP, McFadden E, Brodovsky H, Engstrom P, Hatfield A, Ingle J, Schwartz B, Stolbach L. Cooperative groups and community hospitals: Measurement of impact in the community hospitals. Cancer 1983; 52:1760-1767. [PubMed Abstract]

  26. DeWys WD, Begg CB, Brodovsky H, Creech R, Khandekar J. Comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer - prognostic factors and response. Prostate 1983; 4:1-11. [PubMed Abstract]

  27. Begg CB, Carbone PP. Clinical trials and drug toxicity of the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52:1986-1992. [PubMed Abstract]

  28. Begg CB, Walker AM, Wessen B, Zelen M. Alcohol consumption and breast cancer. Lancet 1983; 1:293-294. [PubMed Abstract]

  29. Epstein AM, Begg CB, McNeil BJ. The effects of group size on test ordering for hypertensive patients. N Engl J Med 1983; 309:464-468. [PubMed Abstract]

  30. Rudders RA, DeLellis RA, Ahl ET, Bernstein S, Begg CB. Adult non-Hodgkins’ lymphoma: correlation of cell surface marker phenotype with prognosis, the new working formulation, and the Rappaport and Lukes Collins histomorphologic schemes. Cancer 1983; 52:2289-2299. [PubMed Abstract]

  31. Begg CB, Gray R. Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika 1984; 71:11-18.

  32. Begg CB, Kalish LA. Treatment allocation for nonlinear models in sequential clinical trials: the logistic model. Biometrics 1984; 40:409-420. [PubMed Abstract]

  33. Gray R, Begg CB, Greenes RA. Construction of receiver operating characteristic curves when disease verification is subject to selection bias. Med Decis Making 1984; 4:151-164. [PubMed Abstract]

  34. Begg CB. Estimation of risks when verification of disease status is obtained in a selected group of subjects. Am J Epidemiol 1984; 120:328-329.

  35. Greenes RA, Cain KC, Begg CB. Patient oriented performance measures of diagnostic tests; 1. Tools for prospective evaluation of test order decisions. Med Decis Making 1984; 4:7-16. [PubMed Abstract]

  36. Greenes RA, Begg CB, Cain KC, Swets JA, Feerer CE, McNeil BJ. Patient oriented performance measures of diagnostic tests: 2. Assignment potential and assignment strength. Med Decis Making 1984; 4:17-32. [PubMed Abstract]

  37. Cain KC, Greenes RA, Begg CB. Patient oriented performance measures of diagnostic tests. 3. Utility factor. Med Decis Making 1984; 4:33-46. [PubMed Abstract]

  38. Begg CB, McGlave PB, Bennett JM, Cassileth PA, Oken MM. A critical comparison of allogeneic bone marrow transplantation and conventional chemotherapy as treatment for acute nonlymphocytic leukemia. J Clin Oncol 1984; 2:369-378. [PubMed Abstract]

  39. Cassileth PA, Begg CB, Bennett JM, Bozdech M, Kahn SB, Bennett JM, Weiler C, Glick JM. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984; 63:843-847. [PubMed Abstract]

  40. Epstein AM, Begg CB, McNeil BJ. The effects of physicians’ training and personality on test ordering for hypertensive patients. Am J Public Health 1984; 74:1271-1273. [PubMed Abstract]

  41. Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner M, Glick JM. Full dose daunorubicin, cytosine Arabinoside, and thioguanine vs. attenuated DAT in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984; 2:865-870. [PubMed Abstract]

  42. Begg CB. A measure to aid in the interpretation of published clinical trials. Stat Med 1985; 4:1-9. [PubMed Abstract]

  43. Kalish LA, Begg CB. Treatment allocation methods in clinical trials: a review. Stat Med 1985; 4:129-144. [PubMed Abstract]

  44. Greenes RA and Begg CB. Assessment of diagnostic technologies: Methodologies for unbiased estimation. Invest Radiol 1985; 20:751-756. [PubMed Abstract]

  45. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making l985; 5:157-177. [PubMed Abstract]

  46. Epstein AM, Begg CB, McNeil BJ. The use of ambulatory testing in prepaid and fee for service group practices. N Engl J Med 1986; 314:1089-1094. [PubMed Abstract]

  47. Begg CB, Greenes RA, and Iglewicz B. The influence of uninterpretability on the assessment of diagnostic tests. J Chronic Dis 1986; 39:575-584. [PubMed Abstract]

  48. Cassileth PA, Begg CB, Silver R, Spiers A, Burkhart PT, Scharfman W, Knopse WH, Bennett JM, Mazza JJ, Oken MM, Keller AM, O’Connel MJ. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia. Cancer Treat Rep 1987; 71:137-140. [PubMed Abstract]

  49. Begg CB, Gray RJ. Methodology for case-control studies with prevalent cases. Biometrika 1987; 74:191-195.

  50. Kalish LA, Begg CB. Evaluation of efficient designs for observational epidemiologic studies. Biometrics 1987; 43:145-168. [PubMed Abstract]

  51. Chu J, Diehr P, Feigl P, Glaefke G, Begg C, Glicksman A, Hunter C, Ford L. The effect of age on the care of women with breast cancer in community hospitals. J Geriatr 1987; 42:185-190. [PubMed Abstract]

  52. Begg CB. Biases in the assessment of diagnostic tests: Stat Med 1987; 6:411-424. [PubMed Abstract]

  53. Kalish LA, Begg CB. The impact of treatment allocation procedures on nominal significance levels and bias. Control Clin Trials 1987; 8:121-135. [PubMed Abstract]

  54. Begg CB, Engstrom PJ. Eligibility and extrapolation in cancer clinical trials. J Clin Oncol 1987; 5:962-968. [PubMed Abstract]

  55. Begg CB. Risk factor analysis of screening data. J Chronic Dis 1987; 40:989-991. [PubMed Abstract]

  56. Henner WD, Shea TC, Furlong EA, Flaherty MK, Eder JP, Elias A, Begg CB, Antman K. Pharmacokinetics of continuous infusion high-dose Thio-TEPA. Cancer Treat Rep 1987; 71:1043-1047. [PubMed Abstract]

  57. Begg CB, Pocock SJ, Freedman SL, Zelen M. The state of the art in comparative cancer clinical trials. Cancer 1987; 60:2811-2815. [PubMed Abstract]

  58. Krontiris TG, DiMartino NA, Mitcheson HD, Lonregan JA, Begg CB, Parkinson DR. Human hypervariable sequences in risk assessment: rare Ha-ras alleles in cancer patients. Environ Health Perspect 1987; 76:147-153. [PubMed Abstract]

  59. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data (with discussion). J Royal Stat Soc: Series A 1988; 151:419-463.

  60. Tosteson AA, Begg CB. A general regression methodology for ROC curve estimation. Med Decis Making 1988; 8:205-215. [PubMed Abstract]

  61. Cassileth PA, Sylvester LS, Bennett JM, Begg CB. High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for central nervous system leukemia. J Clin Oncol 1988; 6:495-498. [PubMed Abstract]

  62. Begg CB, McNeil BJ. Assessment of radiologic tests: control of bias and other design considerations. Radiology 1988; 167:565-569. [PubMed Abstract]

  63. Begg CB. Selection of patients for clinical trials. Semin Oncol 1988; 15:434-440. [PubMed Abstract]

  64. Epstein AM, Stern RS, Tognetti J, Begg CB, Hartley RM, Cumella E, Ayanian J. The association of patients’ socioeconomic characteristics with length of hospital stay and hospital charges with diagnosis related groups. N Engl J Med 1988; 318:1579-1584. [PubMed Abstract]

  65. Walsh SJ, Begg CB, Carbone PP. Issues of cancer chemotherapy in the elderly. Semin Oncol 1989; 16:66-75. [PubMed Abstract]

  66. Mick R, Begg CB, Antman KH, Korzun AH, Frei E. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 1989; 13:33-38. [PubMed Abstract]

  67. Begg CB, Berlin JA. Publication bias and the dissemination of clinical research. J Natl Cancer Inst 1989; 81:107-115. [PubMed Abstract]

  68. Berlin JA, Begg CB, Louis TA. An assessment of publication bias using a sample of published clinical trials. J Amer Stat Assoc 1989; 84:381-392.

  69. Begg CB, Pilote L, McGlave PB. Bone-marrow transplantation versus chemotherapy in acute non-lymphocytic leukemia: a meta-analytic review. Euro J Cancer Clin Oncol 1989; 25:545-550. [PubMed Abstract]

  70. Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E, Henner WD. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7:651-661. [PubMed Abstract]

  71. Begg CB. Experimental design of medical imaging trials: issues and options. Invest Radiol 1989; 24:934-936. [PubMed Abstract]

  72. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman K. High-dose ifosfamide with mesna uroprotection. J Clin Oncol 1990; 8:170-178. [PubMed Abstract]

  73. Begg CB. On inferences from Wei’s biased coin design for clinical trials (with discussion). Biometrika 1990; 77:467-484.

  74. Hunink MGM, Richardson DK, Doublilet PM, Begg CB. Testing for fetal pulmonary maturity: an ROC analysis involving covariates, verification bias, and combination testing. Med Decis Making 1990; 10:201-211. [PubMed Abstract]

  75. Begg CB. Significance tests of covariate imbalance in clinical trials. Control Clin Trials 1990; 11:223-225. [PubMed Abstract]

  76. Begg CB, Pilote L. A model for incorporating historical controls into a meta-analysis. Biometrics 1991; 47:899-906. [PubMed Abstract]

  77. Hunink MGM, Begg CB. Diamond’s correction method: a real gem or just cubic zirconium? Med Decis Making 1991; 11:201-203. [PubMed Abstract]

  78. Fuks Z, Leibel SA, Wallner KE, Begg CB, Fair WR, Anderson LL, Hilaris BS, Whitmore WF. The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys 1991; 21:537-547. [PubMed Abstract]

  79. Dear KBG, Begg CB. An approach for assessing publication bias prior to performing a meta-analysis. Stat Sci 1992; 2:237-245.

  80. Shah JP, Loree TR, Dharker D, Strong EW, Begg CB, Vlamis V. Prognostic factors in differentiated cancer of the thyroid gland. J Urol 1992; 164:658-661. [PubMed Abstract]

  81. Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O’Dell M, Curley T, Dershaw D, Quinlivan S, Tao Y, Fair WR, Begg C, Bosl GJ. Dose-Intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993; 11:408-414. [PubMed Abstract]

  82. Bennett JM, Andersen JW, Begg CB, Glick JH. Age and Hodgkin’s disease: The impact of competing risks and possibly salvage therapy on long term survival: an E.C.O.G. study. Leukemia Research 1993; 17:825-832. [PubMed Abstract]

  83. Begg CB. Methodological issues in studies of the treatment, diagnosis and etiology of prostate cancer. Semin Oncol 1994; 21:569-579. [PubMed Abstract]

  84. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101. [PubMed Abstract]

  85. Li Z, Begg CB. Random effects models for combining results from controlled and uncontrolled studies in a meta-analysis. J Amer Stat Assoc 1994; 89:1523-1527.

  86. Begg CB, Zhang ZF. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev 1994; 3:173-175. [PubMed Abstract]

  87. Zhang ZF, Begg CB. Is trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. Int J Epidemiol 1994; 23:682-690. [PubMed Abstract]

  88. Zhang ZF, Aprikian A, Sarkis AS, Z-S Zeng, Pollack D, Cordon-Cardo C, Fair WR, Begg CB. Factors associated with p53 nuclear accumulation in prostatic adenocarcinoma. Int J Oncol 1994; 4:897-901.

  89. Zhang ZF, Sarkis AS, Cordon-Cardo C, Dalbagni G, Melamed J, Aprikian A, Pollack D, Sheinfeld J, Herr HW, Fair WR, Reuter VE, Begg CB. Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer Epidemiol Biomarkers Prev 1994; 3:19-24. [PubMed Abstract]

  90. Schultz PK, Kelly WK, Begg C, Liebertz C, Cohen L, Scher HI. Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: A trial of 10-Ethyl-Deaza-Aminopterin. Urology 1994; 44:237-242. [PubMed Abstract]

  91. Kraus DH, Dubner S, Harrison LB, Strong EW, Hajdu SI, Kher U, Begg CB, Brennan MF. Prognostic factors for recurrence and survival in head and neck soft tissue sarcomas. Cancer 1994; 74: Vol.2, 697-702. [PubMed Abstract]

  92. Tosteson ANA, Weinstein MC, Wittenberg J, Begg CB. ROC curve regression analysis: The use of ordinal regression models for diagnostic test assessment. Environ Health Perspect 1994; 102:73-78. [PubMed Abstract]

  93. Begg CB, Zhang ZF, Sun M, Herr HW, Schantz SP. Methodology for evaluating incidence of second primary cancers with application to smoking-related cancers from SEER. Am J Epidemiol 1995; 142:653-665. [PubMed Abstract]

  94. Zhang Z-F, Karpeh MS, Lauwers GY, Marrero AM, Pollack D, Cordon-Cardo C, Begg C. Risk factors and p53 nuclear overexpression in early stage intestinal-type adenocarcinoma of the stomach. Cancer Detect Prev 1995; 19(2):156-164 and Ann Acad Sci New York 1995; 768:269-71. [PubMed Abstract]

  95. Zhang Z-F, Zeng Z-S, Sarkis AS, Klimstra DS, Charytonowicz E, Pollack D, Ven J, Guillem J, Marshall JR, Cordon-Cardo C, Cohen AM, Begg, CB. Family history of cancer, body weight, and p53 nuclear overexpression Duke’s C colorectal cancer. Br J Cancer 1995; 71:888-893. [PubMed Abstract]

  96. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996; 88:17-23. [PubMed Abstract]

  97. McCormack P, Bains MS, Begg CB, Burt ME, Downey RJ, Panicek DM, Rusch VW, Zakowski M, Ginsberg RJ. Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of prospective trial. Ann Thorac Surg 1996; 62: 213-217. [PubMed Abstract]

  98. Begg CB. The role of meta-analysis in monitoring clinical trials (with discussion). Stat Med 1996; 15: 1299-1306. [PubMed Abstract]

  99. Yao TJ, Begg CB, Livingston PO. Optimal sample size for a series of pilot trials of new agents. Biometrics 1996;52:992-1001. [PubMed Abstract]

  100. Begg CB, Huang Y, Berwick M. Separate estimation of primary and secondary cancer prevention: analysis of a case-control study of skin self-examination and melanoma. J Amer Stat Assoc 1996:91:1381-1387.

  101. Venkatraman ES, Begg CB. A distribution-free procedure for comparing receiver operating characteristic curves from a paired experiment. Biometrika 1996;83:835-848.

  102. Begg CB, Berwick M. A note on the estimation of relative risks of rare genetic susceptibility markers. Cancer Epidemiol Biomarkers Prev 1997;6:99-103. [PubMed Abstract]

  103. Cookson MS, Sogani PC, Russo P, Sheinfeld J, Herr H, Dalbagni G, Reuter VE, Begg CB, Fair WR. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer results of a Phase II study. Br J Urol 1997; 79: 432-438. [PubMed Abstract]

  104. Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, Russo P, Soloway SM, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg CB, Heston WD, Reuter VE. The indications, rationale, and results of neoadjuvant adrogen deprivation in the treatment of prostatic cancer: Memorial Sloan Kettering Cancer Center results. Urology 1997;49:46-55. [PubMed Abstract]

  105. Denis L, Norlen BJ, Holmberg L, Begg CB, Damber JE, Wilt TJ. Planning controlled clinical trials. Urology 1997;49:15-26. [PubMed Abstract]

  106. Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular non-seminomatous germ cell cancer: assessment of size and distribution criteria. Amer J of Roentg 1997;169:521-525. [PubMed Abstract]

  107. Begg CB, Satagopan JM, Berwick M. A new strategy for evaluating the impact of epidemiologic risk factors for cancer with application to melanoma. J Amer Stat Assoc 1998;93:415-426.

  108. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery (with editorial). JAMA 1998; 280:1747-1751. [PubMed Abstract]

  109. Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, Eisen C. Computed tomography and magnetic resonance imaging staging of malignant pleural mesothelioma. Am J Roentg 1999;172:1039-1047. [PubMed Abstract]

  110. Venkatraman ES, Begg CB. Properties of a nonparametric test for early comparison of treatments in clinical trials in the presence of surrogate endpoints. Biometrics 1999; 55: 1171-1176. [PubMed Abstract]

  111. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AD, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-2751. [PubMed Abstract]

  112. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer (with editorial). N Engl J Med 1999;341:1198-1205. [PubMed Abstract]

  113. Begg CB, Leung DHY. On the use of surrogate endpoints in randomized trials (with discussion). J Royal Stat Soc, Series A 2000; 163:15-28.

  114. Begg CB, Cramer LD, Venkatraman ES, Rosai J. Comparing tumor staging and grading systems: A case study and a review of the issues, using thymoma as a model. Stat Med 2000;19:1997-2014. [PubMed Abstract]

  115. Schrag D, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB. The influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 2000; 284:3028-3035. [PubMed Abstract]

  116. Begg CB. The search for cancer risk factors: when can we stop looking? (with commentaries) Am J Public Health 2001;91:360-364. [PubMed Abstract]

  117. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001;10:467-473. [PubMed Abstract]

  118. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-857. [PubMed Abstract]

  119. Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital procedure volume on survival following resection of lung cancer. New Engl J Med 2001;345:181-188. [PubMed Abstract]

  120. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? (with editorial) J Clin Oncol 2001;19:3712-3718. [PubMed Abstract]

  121. Satagopan JM, Verbel DA, Venkatraman ES, Offit KE, Begg CB. Two-stage designs for gene-disease association. Biometrics 2002;58:163-170. [PubMed Abstract]

  122. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT. Variations in morbidity following radical prostatectomy (with editorial). New Engl J Med 2002; 346:1138-1144. [PubMed Abstract]

  123. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis (with editorial). JAMA 2002;287:2106-2113. [PubMed Abstract]

  124. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance (with editorial). J Natl Cancer Inst 2002;94:1221-1226. [PubMed Abstract]

  125. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002;20:3999-4005. [PubMed Abstract]

  126. Shike M, Latkany L, Riedel E, Fleisher M, Schatzkin A, Lanza E, Corle D, Begg CB. Lack of effect of a low-fat, high-fruit, high-vegetable, and high-fiber diet on serum prostate specific antigen of men without prostate cancer. Results from a randomized trial (with editorial). J Clin Oncol 2002;20:3592-3598. [PubMed Abstract]

  127. Potosky AL, Warren JL, Riedel E, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 2002;40:562-568. [PubMed Abstract]

  128. Schrag D, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, Begg CB. Hospital and surgeon procedure volume as predictors of outcome following rectal-cancer resection. Ann Surg 2002;236:583-592. [PubMed Abstract]

  129. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-478. [PubMed Abstract]

  130. Saunders CL, Begg CB. Kin-cohort evaluation of relative risks of genetic variants. Genet Epidemiol 2003;24:220-229. [PubMed Abstract]

  131. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance for patients with superficial bladder cancer. J Natl Cancer Inst 2003;95:588-597. [PubMed Abstract]

  132. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, Lanza E, Latkany L, Begg CB. Variation of serum prostate specific antigen levels: an evaluation of year-to-year fluctuations in a well defined cohort of men. JAMA 2003;289:2695-2700. [PubMed Abstract]

  133. Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol 2003;83: 68-79. [PubMed Abstract]

  134. Panageas KS, Schrag D, Riedel E, Bach P, Begg CB. Clustering of outcomes in volume-outcome studies: statistical nuisance or outcome of interest (with editorial)? Ann Intern Med 2003;139:658-665. [PubMed Abstract]

  135. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, Gonen M, Reuter V, Scardino PT. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003;170:2292-2295. [PubMed Abstract]

  136. Berwick M, Orlow I, Mahabir S, Myskowski P, Coit D, Brady MS, Roy P, Song Y, Canchola R, Barz A, Halpern A, Bolognia J, Eng S, Elahi A, Begg CB. Estimating the relative risk of developing melanoma in INK4A carriers. Eur J Cancer Prev 2004;13:65-70. [PubMed Abstract]

  137. Satagopan JM, Venkatraman ES, Begg CB. Two-stage designs for gene-disease association studies with sample size constraints. Biometrics 2004;60:589-597. [PubMed Abstract]

  138. Venkatraman ES, Mitra N, Begg CB. A method for evaluating the impact of individual haplotypes on disease incidence in molecular epidemiology studies. Statistical applications in Genetics and Molecular Biology 2004;3:1-20.

  139. Begg CB, Hummer A, Mujumdar U, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Klotz JB, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Berwick M. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control 2004;15:957-965. [PubMed Abstract]

  140. Bach PB, Schrag D, Begg CB. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA 2004;22:2765-2770. [PubMed Abstract]

  141. Bach PB, Elkin EB, Pastorino U, Kattan MW, Mushlin AI, Begg CB, Parkin DM. Benchmarking lung cancer mortality rates in current and former smokers. Chest 2004;126:1742-1749. [PubMed Abstract]

  142. Millikan RC, Hummer AJ, Wolff MS, Hishida A, Begg CB. HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. Breast Cancer Res Treat 2005;89:309-312. [PubMed Abstract]

  143. Bianco FJ Jr, Riedel ER, Begg CB, Kattan MW, Scardino PT. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol 2005;173:2099-2103. [PubMed Abstract]

  144. Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, Begg CB. Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the medicare population. Urology 2005;65:1118-1125. [PubMed Abstract]

  145. Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast cancer survival in the U.S., 1975-1999. Cancer 2005 Sep 15;104(6):1149-57. [PubMed Abstract]

  146. Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample (with editorial). J Natl Cancer Inst 2005; 97:1507-15. [PubMed Abstract]

  147. Millikan RC, Hummer A, Begg C, Player J, René de Cotret A, Winkel S, Mohrenweiser H, Thomas N, Armstrong B, Kricker A, Marrett LD, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Rebbeck T, Busam K, From L, Mujumdar U, Berwick M. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the genes environment and melanoma study. Carcinogenesis, 2006; 27:3 610-618 [PubMed Abstract]

  148. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB,Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, Hall EJ, Hisada M, Inskip P, Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui C, Robison LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Greene MH. Cancer survivorship - genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98:15-25 [PubMed Abstract]

  149. Begg CB, Hummer AJ, Mujumdar U, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Klaus Busam, From L, Berwick M. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int. J. Epidemiol 2006; 35: 756-764. [PubMed Abstract]

  150. Berwick M, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC,Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Busan K, From L, Mujumdar U, Wilcox H, Begg CB for GEM Study Group. The prevalence of CDKN24 germline mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Cancer Epidemiol Biomarkers Prev. 2006; 15:1520-1525. [PubMed Abstract]

  151. Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Busam K, From L, Mujumdar U, Wilcox H, Begg CB, Berwick M. Population-Based Study of Natural Variation in the Melanocortin-1 Receptor Gene and Melanoma. Cancer Res. Cancer Res 2006; 66: 9330-9337 [PubMed Abstract]

  152. Begg CB, Eng KH, Hummer AJ. Statistical tests for clonality. Biometrics 2007 June; 63(2): 522-530 [PubMed Abstract]

  153. Panageas KS, Schrag D, Localio AR, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med. 2007 April 30; 26(9): 2017-2035. [PubMed Abstract]

  154. Orlow I, Begg CB, Cotignola J, Pampa R, Hummer AJ, Clas BA, Mujumdar U, Canchola R, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Kanetsky PA, Wilcox H, Busam K, From L, Berwick M for GEM Study Group. CDKN24 Germline Mutations in Individuals with Cutaneous Malignant Melanoma. Investigative Dermatology, 2007 May; 127(5): 1234-1243. [PubMed Abstract]

  155. Kricker A, Armstrong BK, Goumas C, Litchfield M, Begg CB, Hummer AJ, Marrett LD, Theis B, Millikan RC, Thomas N, Anton-Culver H, Gallagher RP, Dwyer T, Rebbeck TR, Busam K, From L, Mujumdar U, Zanetti R, Berwick M. “Ambient UV, personal sun exposure and risk of multiple primary melanomas.” Cancer Causes and Control 2007 April; 18(3): 295-304. [PubMed Abstract]

  156. Largent JA, Capanu M, Bernstein L, Langholz, B, Mellemkjaer L, Malone KE, Begg CB, Haile RW, Lynch CF, Anton-Culver H, Wolitzer A, Bernstein JL. Reproductive history and risk of second primary breast cancer: the WECARE Study. Cancer Epidemiology Biomarkers and Prevention 2007; 16:906-911 [PubMed Abstract]

  157. Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben P, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer AJ, Conway K. Number of Nevi and Early Life Ambient UV Exposure are Associated with BRAF Mutations in Melanomas. Cancer Epidemiol Biomark Prev 2007; 16:991-997 [PubMed Abstract]

  158. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. (with editorial) JAMA 2007; 297:953-961 [PubMed Abstract]

  159. Moskowitz CS, Seshan VE, Riedel ER, Begg CB. Estimating the empirical Lorenz curve and Gini coefficient in the presence of error with nested data. Statistics in Medicine 2008;27:3191-3208. [PubMed Abstract]

  160. Capanu M, Orlow I, Berwick M, Hummer AJ, Thomas DC, Begg CB. The use of hierarchical models for estimating relative risks of individual genetic variants: an application to a study of melanoma. Statistics in Medicine 2008; 27:1973-1992. [PubMed Abstract]

  161. Bertelsen L, Bernstein L, Olsen JH, Mellenkjaer L, Haile R, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholy B, Thomas DC, Begg CB, Capanu M, Ejlertser B, Stovall M, Boice JD, Share RE, Bernstein JL. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the WECARE study. Journal of the National Cancer Institute 2008; 100:32-40. [PubMed Abstract]

  162. Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF, Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL. Variation of breast cancer risk among BRCA1/2 carriers: An investigation by the WECARE Study Group. JAMA 2008; 299:194-201. [PubMed Abstract]

  163. Orlow I, Park BJ, Mujumdar U, Patel H, Siu-Lau P, Clas BA, Downey R, Flores R, Bains M, Rizk N, Dominguez G, Jani J, Berwick M, Begg CB, Kris MG, Rusch VW. DNA damage and repair capacity in patients with lung cancer patients: Prediction of multiple primary tumors. Journal of Clinical Oncology 2008; 26:3560-3566. [PubMed Abstract]

  164. Ostrovnaya I, Seshan VE, Begg CB. Comparison of properties of test for assessing tumor clonality. Biometrics 2008; 64:1018-1022. [PubMed Abstract]

  165. Elkin EB, Ishill N, Riley GF, Bach PB, Gonen M, Begg CB, Schrag D. Disenrollment From Medicare Managed Care Among Beneficiaries With and Without a Cancer Diagnosis. Journal of the National Cancer Institute 2008; 100:1013-1021 [PubMed Abstract]

  166. Concannon P, Haile RW, Borresen-Dale A-L, Rosenstein BS, Gatti RA, Teraoka SN, Diep AT, Jansen L, Atencio DP, Langholz B, Capanu M, Liang X, Begg CB, Thomas DC, Bernstein L, Olsen JH, Malone KE, Lynch CF, Anton-Culver H, Bernstein JL for the Women’s Environment, Cancer, and Radiation Epidemiology Study Collaborative Group. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Research 2008; 68: 6486-6491. [PubMed Abstract]

  167. Orlow I, Tommasi D, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. In press, Journal of Investigative Dermatology. 2009;129:1972-1982 [PubMed Abstract]

  168. Mujumdar UJ, Hay JL, Monroe-Hinds YC, Hummer AJ, Begg CB, Wilcox HB, Oliveria SA, Berwick M. Sun protection and skin self-examination in melanoma survivors. Psycho Oncology 2009;18:1106-1115. [PubMed Abstract]

  169. Knight JA, Bernstein L, Largent J, Capanu M, Begg CB, Mellemkjaer L, Lynch CF, Malone KE, Reiner AS, Liang X, Haile RW, Boice Jr. JD, WECARE Study Collaborative Group, Bernstein JL. Alcohol intake and cigarette smoking and risk of a contralateral breast cancer: the women’s environmental cancer and radiation epidemiology study. American Journal of Epidemiology 2009;169:962-968. [PubMed Abstract]

  170. Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W, Begg CB. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clinical Cancer Research 2009;15:5184-5190. [PubMed Abstract]

  171. Kuligina E, Reiner A, Imyanitov EN, Begg CB. Evaluating cancer epidemiologic risk factors using multiple primary malignancies. Epidemiology 2010;21:366-372. [PubMed Abstract]

  172. Ostrovnaya I, Begg CB. Testing clonal relatedness of tumors using array CGH: A statistical challenge. Clinical Cancer Research 2010;16:1358-1367. [PubMed Abstract]

  173. Malone ME, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner AS, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice Jr. JD, Anton-Culver H, Bernstein JL. A population-based study of the risk of secondary primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. Journal of Clinical Oncology 2010;28:2404-2410. [PubMed Abstract]

  174. Borg A, Haile RW, Malone KE, Capanu M, Diep A, Torngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L, Bernstein L, Tellhed L, Xue S, Olson ER, Liang X, Dolle J, Borresen-Dale, A-L, The WECARE Study Collaborative Group, Bernstein JL. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: The WECARE study. Human Mutation 2010 Jan 26;31(3):E1200-E1240. [PubMed Abstract]

  175. Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD, Stovall M, Andersson M, Bernstein L, Malone KE, Reiner AS, Lynch CF, Capanu M, Smith SA, Tellhed L, Xue S, Teraoka SN, Begg CB, Olsen JH, Mellemkjaer L, Xiang X, Olson E, Diep AT, The WECARE Study Collaborative Group, Borg A, Concannon P, Haile RW. Radiation-induced second primary breast cancer and BRCA1 and BRCA2 mutation carrier status: A report from the WECARE study. Journal of the National Cancer Institute, in press.

  176. Ostrovnaya I, Olshen AB, Seshan VE, Orlow I, Albertson DG, Begg CB. A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data. Statistics in Medicine 2010;29:1608-1621. [PubMed Abstract]

  177. Poynter JN, Langholz B, Largent J, Mellemkjaer L, Bernstein L, Malone KE, Lynch CF, Borg A, Concannon P, Teraoka SN, Xue S, Diep AT, Torngren T, Begg CB, Capanu M, Haile RW, WECARE Study Collaborative Group, Bernstein JL. Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study. Cancer Causes Control 2010;21:839-46. [PubMed Abstract]

  178. Kricker A, Armstrong B, Goumas C, Kanetsky P, Gallagher RP, Begg CB, Millikan RC, Dwyer T, Rosso S, Marrett LD, Thomas NE, Berwick M for the GEM Study Group. MC1R genotype may modify the effect of sun exposure on melanoma risk in the GEM study. Cancer Causes and Control 2010;21:2137-47. [PubMed Abstract]

  179. Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, Zelefsky MJ, Scardino PT, Begg CB, Schrag D. Physician visits prior to treatment for clinically localized prostate cancer. Archives of Internal Medicine 2010; 170:440-450.

  180. Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Törngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE; WECARE Collaborative Study Group. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Research and Treatment 2010; 123:491-498. [PubMed Abstract]

  181. Thomas NE, Kricker A, From L, Busam KJ, Millikan RC, Ritchey ME, Armstrong BK, Lee-Taylor J, Marrett L, Anton-Culver H, Zanetti R, Rosso S, Gallagher RP, Dwyer T, Goumas C, Kanetsky PA, Begg CB, Orlow I, Wilcox H, Paine S, Berwick M. Associations of cumulative sun exposure and phenotypic characteristics with histologic solar elastosis. Cancer Epidemiology Biomarkers & Prevention 2010;19:2932-41. [PubMed Abstract]

  182. Capanu M, Begg CB. Hierarchical modeling for estimating relative risks of rare genetic variants: properties of the pseudo-likelihood method. Biometrics 2011;67:371-380. [PubMed Abstract]

  183. Begg, CB. A strategy for distinguishing optimal cancer sub-types. International Journal of Cancer 2011;129:931-937. [PubMed Abstract]

  184. Vickers AJ, Cronin AM, Begg CB. One statistical test is sufficient for assessing new predictive markers. BMC Medical Research Methodology 2011;11:13. [PubMed Abstract]

  185. Mandelcorn-Monson R, Marrett L, Kricker A, Armstrong B, Orlow I, Goumas C, Paine S, Rosso S, Thomas N, Millikan RC, Pole JD, Cotignola J, Rosen C, Kanetsky P, Begg CB, Berwick M for the GEM Study Group. Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. Cancer Epidemiology. 2011;35:e105-110. [PubMed Abstract]

  186. Capanu M, Concannon P, Haile RW, Bernstein L, Malone KE, Lynch CF, Liang X, Teraoka SN, Diep AT, Thomas DC, Bernstein JL, The WECARE Study Collaborative Group, Begg CB. Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling. Genetic Epidemiology 2011;35:389-397. [PubMed Abstract]

  187. Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Thomas NE, Gruber SB, Anton-Culver H, Rosso S, Gallagher RP, Dwyer T, Kanetsky PA, Busam K, From L, Begg CB, Berwick M; for the GEM Study Group. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. International Journal of Cancer 2012;130:405-418. [PubMed Abstract]

  188. Ostrovnaya I, Seshan VE, Olshen A, Begg CB. Clonality: an R package for testing clonal relatedness of two tumors from the same patient based on their genomic profiles. Bioinformatics 2011;27:1698-1699. [PubMed Abstract]

  189. Artzrouni M, Begg CB, Chabiniok R, Clairambault J, Foss A, Hargrove J, Lee EK, Siggers JH, Tindall M. The first international workshop on the role and impact of mathematics in medicine: a collective account. American Journal of Translational Research 2011;3:492-497.

  190. Berwick M, Begg CB, Armstrong BK, Reiner AS, Thomas NE, Cook LS, Orlow I, Kricker A, Marrett LD, Gruber SB, Anton-Culver H, Millikan RC, Gallagher RP, Dwyer T, Rosso S, Kanetsky PA, Lee-Taylor J. Interaction of CDKN2A and sun exposure in the etiology of melanoma in the general population. Journal of Investigative Dermatology 2011;131:2500-2503. [PubMed Abstract] [Available on 2012/6/1]

  191. Murali R, Goumas C, Kricker A, From L, Busam KJ, Begg CB, Dwyer T, Gruber SB, Kanetsky PA, Orlow I, Rosso S, Thomas NE, Berwick M, Scolyer RA, Armstrong BK; For the GEM Study Group. Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Annals of Surgical Oncology 2012;19:1024-1033. [PubMed Abstract] [Available on 2013/3/1]

  192. Begg CB, Zabor E. Detecting and exploiting etiologic heterogeneity in epidemiologic studies. American Journal of Epidemiology 2012 (in press).

  193. Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallee M, Tavtigian S, Concannon P, Foulkes WD, Bernstein L, Bernstein JL, Begg CB. Rare germline mutations in PALB2 and breast cancer risk: A population-based study. Human Mutation 2012 Jan 12. [epub ahead of print].

My Downloads

My Events